Antipsychotic use in patients with schizophrenia treated in private psychiatry

Swiss Medical Weekly

Volumn 135, Issue 7-8, 2005, Pages 109-115

  Simon, Andor E ^a   Peter, Manuela ^b   Hess, Lorenzo ^b   Valterio, Claude ^c  

^a Externe Psychiat Dienste Baselland   (Switzerland)

^b Brunner and Hess Software AG   (Switzerland)

^c Sanofi Synthélabo Switzerland   (Switzerland)

Author keywords

Antipsychotics; Comedication; Non adherence; Non compliance; Polypharmacy; Private practice; Schizophrenia

Indexed keywords

ANTIDEPRESSANT AGENT; ATYPICAL ANTIPSYCHOTIC AGENT; HYPNOTIC SEDATIVE AGENT; MOOD STABILIZER; NEUROLEPTIC AGENT; TRANQUILIZER;

ADULT; ARTICLE; DEMOGRAPHY; DOCUMENTATION; DRUG USE; FEMALE; HEALTH SURVEY; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAL PRACTICE; MONOTHERAPY; PATIENT COMPLIANCE; POLYPHARMACY; PRACTICE GUIDELINE; PRIVATE PRACTICE; PSYCHIATRIC DIAGNOSIS; PSYCHIATRIST; SCHIZOPHRENIA; SEX DIFFERENCE; SIDE EFFECT; SWITZERLAND;

EID: 14744304685     PISSN: 14247860     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (38)

1. Möller HJ. Review: Treatment of schizophrenia. State of the art. Eur Arch Psychiatry Clin Neurosci 1996;246:229-34.
2. Kane JM, Honigfeld G, Singer J, Meltzer H, and the Clozaril Collaborative study group. Clozapine for the treatment-resistant schizophrenic: a double-blind comparison with chlorpromazine. Arch Gen Psychiatry 1988;45:789-96.
3. McEvoy JP, Scheifler PL, Frances A, eds. The Expert Consensus Guideline Series: Treatment of schizophrenia. J Clin Psychiatry 1999;60(Suppl. 11):4-80.
4. Leucht S, Pitschel-Walz G, Abraham D, Kissling W. Efficacy and extrapyramidal side-effects of the new antipsychotics olanzapine, quetiapine, risperidone, and sertindole compared to conventional antipsychotics and placebo. A meta-analysis of randomized controlled trials. Schizophren Res 1999;35:51-68.
5. Davis JM, Chen N, Glick ID. A meta-analysis of the efficacy of second-generation antipsychotics. Arch Gen Psychiatry 2003;60:553-64.
6. Leucht S, Barnes TRE, Kissling W, Engel RR, Correll C, Kane JM. Relapse prevention in schizophrenia with new-generation antipsychotics: a systemic review and exploratory meta-analysis of randomized, controlled trials. Am J Psychiatry 2003;160:1209-22.
7. Bahlo E, Bausch J, Brech W, Brosig A, Dabrock P, Deckert C, et al. Berliner Empfehlungen. In: Dierks C (editor): Innovationen in der Therapie der Schizophrenie. Stuttgart: Schattauer 2001; p. 77-79.
8. Hamann J, Ruppert A, Aubry P, Pugner K, Kissling W. Antipsychotic prescribing patterns in Germany: a retrospective analysis using a large outpatient prescription database. Int Clin Psychopharmacology 2003;18:237-42.
9. Clark RE, Bartels SJ, Mellman TA, Peacock WJ. Recent trends in antipsychotic combination therapy of schizophrenia and schizoaffective disorder: implications for state mental health policy. Schizophren Bull 2002;28:75-84.
10. Meltzer HY, Kostakoglu AE. Combining antipsychotics: Is there evidence for efficacy? Psychiatric Times 2000;9:25-31.
11. Waddington JL, Youssef HA, Kinsella A. Mortality in schizophrenia. Antipsychotic polypharmacy and absence of adjunctive anticholinergics over the course of a 10-year prospective study. Br J Psychiatry 1998;173:325-9.
12. Cramer JA, Rosenheck R. Compliance with medication regimens for mental and physical disorders. Psychiatr Serv 1998;49:196-201.
13. Killaspy H, Banerjee S, King M, Lloyd M. Prospective controlled study of psychiatric outpatient non-attendance. Br J Psychiatry 2000;176:160-5.
14. Brekke JS, Ansel M, Long J, Slade E, Weinstein M. Intensity and continuity of services and functional outcomes in the rehabilitation of persons with schizophrenia. Psychiatr Serv 1999;50:248-56.
15. Nosé M, Barbui C, Tansella M. How often do patients with psychosis fail to adhere to treatment programmes? A systematic review. Psychol Medicine 2003;33:1149-60.
16. Simon AE, Berger GE, Giacomini V, Ferrero FP, Mohr S. Insight and its relationship to psychosocial adjustment in schizophrenia. J Nerv Ment Dis 2004;192:442-5.
17. Kampman O, Lehtinen K. Compliance in psychoses. Acta Psychiatr Scand 1999;100:167-75.
18. Perkins DO. Adherence to antipsychotic medications. J Clin Psychiatry 1999;60(Suppl. 21):25-30.
19. Oehl M, Hummer M, Fleischhacker WW. Compliance with antipsychotic treatment. Acta Psychiatr Scand 2000;102(Suppl. 407):83-6.
20. Kane JM. Extrapyramidal side effects are unacceptable. Eur Neuropsychopharmacol 2001;11(Suppl. 4):S397-S403.
21. Correll CU, Leucht S, Kane JM. Lower risk for tardive dyskinesia associated with second-generation antipsychotics: a systematic review of 1-year studies. Am J Psychiatry 2004;161:414-25.
22. Dolder CR, Lacro JP, Dunn LB, Jeste DV. Antipsychotic medication adherence: is there a difference between typical and atypical agents? Am J Psychiatry 2002;159:103-8.
23. Naber D, Karow A. Good tolerability equals good results: the patient's perspective. Eur Neuropsychopharmacol 2001;11(Suppl. 4):S391-S396.
24. Kurzthaler I, Fleischhacker WW. The clinical implications of weight gain in schizophrenia. J Clin Psychiatry 2001;62(suppl.7):32-7.
25. Nasrallah HA. Factors in antipsychotic drug selection: tolerability considerations. CNS Spectr 2003;8(11 Suppl. 2):23-5.
26. Penn Corrigan 2002 Penn, D.L. & Corrigan, P.W. The effects of stereotype suppression on psychiatric stigma. Schizophrenia Research 2002;55:269-76.
27. Fowler FJ. Survey Research Methods (3rd Edition), pp. 64ff. Thousand Oaks, CA: SAGE Publications, Inc.
28. Statistisches Jahrbuch der Schweiz 2001. 1. Bevölkerung. Verlag Neue Zürcher Zeitung; 2001.
29. Langsley DG. Comparing clinic and private practice of psychiatry. Am J Psychiatry 1978;135:702-6.
30. Tapp A, Wood AE, Secrest L, Erdmann J, Cubberley L, Kilzieh N. Combination antipsychotic therapy in clinical practice. Psychiatr Serv 2003;54:55-9.
31. Gaebel W, Riesbeck M, Janssen B, Schneider F, Held T, Mecklenburg H, et al. Atypical and typical neuroleptics in acute schizophrenia and related delusional disorders. Drug choice, switching and outcome under naturalistic treatment conditions. Eur Arch Psychiatry Clin Neurosci 2003;253:175-84.
32. Frangou, S, Lewis M. Atypical antipsychotics in ordinary clinical practice: a pharmaco-epidemiologic survey in a south London service. Eur Psychiatry 2000;15:220-6.
33. Kissling W, Hoffler J, Seemann U, Muller P, Ruther E, Trenckmann A, et al. Direct and indirect costs of schizophrenia. Fortschr Neurol Psychiatr 1999;67:29-36.
34. Shiloh R, Zemishlany Z, Aizenberg D, Radwan M, Schwartz B, Dorfman-Etrog P, et al. Sulpride augmentation in people with schizophrenia partially responsive to clozapine: a double-blind, placebo-controlled study. Br J Psychiatry 1997;171:569-73.
35. Birchwood M, Todd P, Jackson C. Early intervention in psychosis. The critical period hypothesis. Br J Psychiatry 1998;172(Suppl.):53-9.
36. Kissling W. Compliance, quality assurance and standards for relapse prevention in schizophrenia. Acta Psychiatr Scand 1994;89(suppl. 382):16-24.
37. Ramseier F. [Our knowledge is patchwork. Survey on the adherence to international guidelines concerning acute and long-term therapy in recurrent depressions and diseases in the schizophrenic field]. Schweiz Rundsch Med Prax 1996;85:792-7.
38. Freudenreich O, Cather C, Evins AE, Henderson DC, Goff DC. Attitudes of schizophrenic outpatients towards psychiatric medications: relationship to clinical variables and insight. J Clin Psychiatry 2004;65:1372-6.